| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/21/2002 | US20020035089 Orlistat compositions |
| 03/21/2002 | US20020035086 Acylated uridine and cytidine and uses thereof |
| 03/21/2002 | US20020035085 Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof |
| 03/21/2002 | US20020035067 In ilio-hypogastric-pudendal arterial bed and genitalia by administering to humans therapeutically effective amount of anti-pressor agent |
| 03/21/2002 | US20020035065 Selective MMP inhibitors having reduced side-effects |
| 03/21/2002 | US20020035064 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/21/2002 | US20020035059 For achieving circadian rhythm phase-shifting effect in mammal |
| 03/21/2002 | US20020035057 Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions |
| 03/21/2002 | US20020034806 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 03/21/2002 | US20020034803 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | US20020034779 Novel argS |
| 03/21/2002 | US20020034778 Peptide; for use in drug screening; for use as a diagnostic tool; for use in the treatment of nervous system disorders |
| 03/21/2002 | US20020034777 Modulator of use in the diagnosis, prevention and treatment of inflammation, cancer and nervous system disorders; hypotensive agent |
| 03/21/2002 | US20020034772 Methods and compositions that affect melanogenesis |
| 03/21/2002 | US20020034764 Diarylsulfonylurea binding proteins |
| 03/21/2002 | US20020034758 Novel human genes and gene expressions products: II |
| 03/21/2002 | US20020034736 Nucleotide sequences coding modulators for use in therapy against tumors, retinopathy, perfusion injuries, fibrosis, artherosclerosis, angiogenesis, inflammation, and restenosis; antiischemic and antitumor agents |
| 03/21/2002 | US20020034725 Sensitization of cells to radiation and and chemotherapy |
| 03/21/2002 | US20020034555 Acetaminophen or non-steroidal antiinflammatory drug, and a nutraceutical of a antivasospastic agent or a vascular dilator, and an antinausea agent or live protectant |
| 03/21/2002 | US20020034546 Pharmaceutical composition containing a combination of a statin and aspirin and method |
| 03/21/2002 | US20020034541 Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
| 03/21/2002 | US20020034538 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations |
| 03/21/2002 | US20020034504 Suppressor cells for prevention and treatment of immune responses in transplantation |
| 03/21/2002 | US20020034499 Nutrient medium which can be used as a culture medium for epidermal cells and applications |
| 03/21/2002 | US20020034474 Drug targeting system, method of its preparation and its use |
| 03/21/2002 | US20020033181 Treatment of hepatitis C using hyperthermia |
| 03/21/2002 | US20020033174 Inhalable aerosol medicament for the treatment or prevention of pain |
| 03/21/2002 | US20020033144 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 03/21/2002 | DE10045047A1 Arzneimittel enthaltend aktiviertes Antithrombin III Medicines containing activated antithrombin III |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422278A1 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | CA2422275A1 Compositions and methods for inhibition of hiv-1 infection |
| 03/21/2002 | CA2422246A1 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | CA2422163A1 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | CA2422152A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422068A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | CA2422064A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 03/21/2002 | CA2422053A1 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421751A1 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 03/21/2002 | CA2421585A1 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | CA2421234A1 Interferon-alpha induced gene |
| 03/21/2002 | CA2420459A1 Novel dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 03/21/2002 | CA2419894A1 Process for high throughput screening of cpg-based immuno-agonist/antagonist |
| 03/21/2002 | CA2416563A1 Pharmaceutical composition having specific water activity |
| 03/21/2002 | CA2357467A1 Methods for treating osteoarthritis using an estrogen agonist/antagonist |
| 03/20/2002 | EP1188769A2 High resolution crystal structure of the ribosome and design of protein synthesis inhibitors |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1187918A1 Tek antagonists |
| 03/20/2002 | EP1187915A2 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 03/20/2002 | EP1187912A1 In vivo insect model system for type-2 diabetes |
| 03/20/2002 | EP1187911A2 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 03/20/2002 | EP1187842A1 Human tumor necrosis factor receptor tr10 |
| 03/20/2002 | EP1187827A1 Antiviral agents |
| 03/20/2002 | EP1187637A2 Alpha or beta emitters attached to fragments in radioimmunotherapy |
| 03/20/2002 | EP1187635A1 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist |
| 03/20/2002 | EP1187634A1 Cell growth inhibition |
| 03/20/2002 | EP1187632A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/20/2002 | EP1187628A2 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 03/20/2002 | EP1187627A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 03/20/2002 | EP1187622A1 Method of sterilizing |
| 03/20/2002 | EP1187621A1 Novel pharmaceutical combination based on erythromycin and a carboxylic acid having 7 to 13 carbon atoms |
| 03/20/2002 | EP1187620A1 Antisense modulation of b7 protein expression |
| 03/20/2002 | EP1187619A1 Anti-tumor agents comprising boroproline compounds |
| 03/20/2002 | EP1187615A2 Immunosurpressive effects of pteridine derivatives |
| 03/20/2002 | EP1187610A2 Use of ion channel modulating agents |
| 03/20/2002 | EP1187605A1 Non-malignant disease treatment with ras antagonists |
| 03/20/2002 | EP1187601A1 Novel preparation and administration form comprising an acid-labile active compound |
| 03/20/2002 | EP1187591A2 Ibd-associated microbial antigens and methods of using same |
| 03/20/2002 | EP1187539A1 Method and composition for masking mineral taste |
| 03/20/2002 | EP1019050B1 Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| 03/20/2002 | EP0871446B1 Use of eliprodil for the manufacture of a medicament for the treatment of ischemic disorders of the retina or the optic nerve |
| 03/20/2002 | EP0800829B1 Antitumor agent potentiator comprising il-6 antagonist |
| 03/20/2002 | EP0730458B1 Use of aldosterone antagonists to inhibit myocardial fibrosis |
| 03/20/2002 | EP0418316B1 Platelet-specific chimeric immunoglobulin |
| 03/20/2002 | CN1341027A Inhibitors for use in hemostasis and immune function |
| 03/20/2002 | CN1341026A Small peptides and methods for treatment of asthma and inflammation |
| 03/20/2002 | CN1341024A Methods of treamtment of mitochondrial disorders |
| 03/20/2002 | CN1341020A Anti-tumor synergetic composition |
| 03/20/2002 | CN1341019A Antitumour synergistic composition |
| 03/20/2002 | CN1341017A Combinations of formoterol and mometasone furoate for sathma |
| 03/20/2002 | CN1341013A Method of preparing particles for agglomeration |
| 03/20/2002 | CN1340361A Process for preparing xenomal or autogenous tumor vaccine of liposome |
| 03/19/2002 | US6359127 Oligonucleotide for use in treatment of cancer and nervous system disorders |
| 03/19/2002 | US6359116 Compounds |
| 03/19/2002 | US6359017 Dietary compositions and methods |
| 03/19/2002 | US6359016 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 03/19/2002 | US6359014 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 03/19/2002 | US6359003 Fumaric acid alkyl esters for suppressing host versus graft reaction |
| 03/19/2002 | US6359002 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 03/19/2002 | US6359001 Use of α-methyl-p-tyrosine to inhibit melanin production in iris melanocytes |
| 03/19/2002 | US6358990 Method for treating Alzheimer's disease |
| 03/19/2002 | US6358970 Integrin receptor antagonists |